INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 166 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $475 | +101.3% | 25,642 | +45.6% | 0.05% | +88.0% |
| Q1 2023 | $236 | -99.9% | 17,609 | -10.4% | 0.02% | 0.0% |
| Q3 2022 | $274,000 | -0.4% | 19,656 | +64.9% | 0.02% | +31.6% |
| Q1 2021 | $275,000 | +12.2% | 11,921 | +20.3% | 0.02% | -26.9% |
| Q4 2020 | $245,000 | -79.6% | 9,911 | -60.4% | 0.03% | -81.3% |
| Q2 2020 | $1,199,000 | +391.4% | 25,025 | +580.0% | 0.14% | +631.6% |
| Q3 2019 | $244,000 | -32.0% | 3,680 | +14.7% | 0.02% | -5.0% |
| Q1 2019 | $359,000 | -33.3% | 3,209 | -39.9% | 0.02% | -31.0% |
| Q4 2018 | $538,000 | +142.3% | 5,342 | +101.5% | 0.03% | +190.0% |
| Q2 2018 | $222,000 | -5.1% | 2,651 | -33.8% | 0.01% | -16.7% |
| Q4 2017 | $234,000 | -33.5% | 4,003 | +174.7% | 0.01% | -61.3% |
| Q2 2015 | $352,000 | – | 1,457 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |